Preliminary observations for a new treatment in children with primary intracranial yolk sac tumor or embryonal carcinoma
Authors:
- Yukitaka UshioYUYukitaka Ushio
- Masato KochiMKMasato Kochi
- Jun-Ichi KuratsuJKJun-Ichi Kuratsu
- Youichi ItoyamaYIYouichi Itoyama
- Toru MarubayashiTMToru Marubayashi
- 1 January 1999
- journal article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 90 (1) , 133-137
Abstract
✓ The authors evaluated the effect of adjuvant therapy (preoperative chemotherapy combined with radiotherapy) followed by radical tumor removal in the treatment of children with primary intracranial yolk sac tumor, embryonal carcinoma, or mixed germ cell tumors containing yolk sac tumor components.Between 1988 and 1995, five consecutive patients were treated with adjuvant therapy followed by total tumor removal. The diagnosis was based on markedly elevated concentrations of serum α-fetoprotein (AFP) and/or β-human chorionic gonadotropin (β-HCG) in four children and the results of biopsy sampling in one child. The chemotherapy regimen consisted of cisplatin (20 mg/m2) and etoposide (60 mg/m2) daily for 5 days (one course) given three times at 4-weeks intervals. Radiotherapy consisted of 30 to 40 Gy to the whole brain or an area including all ventricles and a 15- to 20-Gy boost to the tumor site. Spinal radiation of 25 Gy was added in one patient. In all patients the serum level of AFP and β-HCG gradually decreased during the adjuvant therapy and disappeared completely on its completion. In two of the five patients the tumor disappeared as well. In the other three patients the tumor size was moderately or markedly reduced and the remaining tumor was totally removed; there were no neurological deficits. Chemotherapy was maintained after the initial treatment and was repeated every 2 to 4 months for less than 2 years. All children are alive and well without recurrence at 33 to 118 months (average 88 months) after the start of adjuvant therapy.Our preliminary results indicate that adjuvant therapy consisting of combination chemotherapy with cisplatin and etoposide and concomitant radiotherapy, followed by removal of the tumor, is highly effective in the treatment of pediatric patients with primary intracranial yolk sac tumor, embryonal carcinoma, or mixed germ cell tumors containing yolk sac tumor components.Keywords
This publication has 13 references indexed in Scilit:
- Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified casesJournal of Neurosurgery, 1997
- Epidemiological study of primary intracranial tumors: a regional survey in Kumamoto Prefecture in the southern part of JapanJournal of Neurosurgery, 1996
- Epidemiological Study of Primary Intracranial Tumors in ChildhoodPediatric Neurosurgery, 1996
- Treatment of Intracranial Nongerminomatous Malignant Germ Cell Tumors Producing α-FetoproteinNeurosurgery, 1995
- Intracranial Germ Cell Tumors: A Comprehensive Update of the European DataNeuropediatrics, 1994
- Combination chemotherapy with cisplatin and etoposide for malignant intracranial germ-cell tumorsJournal of Neurosurgery, 1989
- Role of Tumor Markers in the Management of Primary Intracranial Germ Cell Tumors1987
- Intracranial germ-cell tumors: natural history and pathogenesisJournal of Neurosurgery, 1985
- Primary pineal endodermal sinus tumor with elevated serum and CSF alphafetoprotein levelsJournal of Neurosurgery, 1980
- Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular CancerAnnals of Internal Medicine, 1977